Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Boehringer Ingelheim
Teva
Accenture
Healthtrust
Cantor Fitzgerald

Generated: August 21, 2019

DrugPatentWatch Database Preview

Patent: 7,732,163

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,732,163
Title:Extracellular serine protease
Abstract: The present invention provides a DNA encoding a novel extracellular serine protease termed Tumor Antigen Derived Gene-14 (TADG-14) which is overexpressed in ovarian, breast and colon carcinoma samples. Also provided are vector and host cells capable of expressing the DNA of the present invention, as well as the uses of the DNA and protein of the present invention. Also provided is a TADG-14 protein variant that has a potential role for detecting and targeting of ovarian carcinomas.
Inventor(s): O\'Brien; Timothy J. (Little Rock, AR), Underwood; Lowell J. (Little Rock, AR), Beard; John (Little Rock, AR), Shigemasa; Kazushi (Hiroshima, JP)
Assignee: Board of Trustees of The University of Arkansas (Little Rock, AR)
Application Number:10/652,846
Patent Claims:see list of patent claims

Details for Patent 7,732,163

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Try a Free Trial Board of Trustees of The University of Arkansas (Little Rock, AR) 2017-08-21 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Try a Free Trial Board of Trustees of The University of Arkansas (Little Rock, AR) 2017-08-21 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Try a Free Trial Board of Trustees of The University of Arkansas (Little Rock, AR) 2017-08-21 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 7,732,163

Country Patent Number Publication Date
World Intellectual Property Organization (WIPO) 9909138 Feb 25, 1999
United States of America 2002037581 Mar 28, 2002
United States of America 2003199010 Oct 23, 2003
United States of America 2006068483 Mar 30, 2006
United States of America 2006154279 Jul 13, 2006
United States of America 2006205054 Sep 14, 2006
United States of America 2010120030 May 13, 2010
>Country >Patent Number >Publication Date

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Cipla
Queensland Health
Chinese Patent Office
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.